Monitoring antitumour immune response during immunotherapy of cancer: Why and how?

BioDrugs

Volumn 11, Issue 4, 1999, Pages 239-247

  DeMatos, Pierre ^a   Seigler, Hilliard F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; HUMAN; IMMUNE RESPONSE; MELANOMA; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0032900136     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911040-00003     Document Type: Review

References (31)

1. 1. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autulogous melanoma cells by tumor infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst 1991 Jul 3; 83 (13): 932-7
2. 2. Gohring B, Riemann D, Rebmann U, et al. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-α-2 in combination with 5-FU. Urol Res 1996 Oct; 24 (5): 297-303
3. 3. Schwartzentruber DJ, Hom SS, Dadmarz R, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and inlerleukin-2. J Clin Oncol 1994 Jul; 12 (7): 1475-83
4. 4. Salgaller ML, Marincola FM, Cormier JN, et al. Immunization against epitopes in the human melanoma antigen gp 100 following patient immunization with synthetic peptides. Cancer Res 1996 Oct 15; 56 (20): 4749-57
5. 5. Barth A, Hoon DS, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994 Jul 1; 54: 3342-5
6. 6. Hoover Jr HC, Surdyke M, Dangel RB, et al. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal patients immunized with an autologous tumor cell-Bacillus Calmette-Guérin vaccine. Cancer Res 1984 Apr; 44: 1671-6
7. 7. Jessup JM, McBride CM, Ames FC, et al. Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine. Cancer Immunol Immunother 1986 Apr; 21 (3): 233-9
8. 8. Bloemena E, Gall H, Ransom JH, et al. Delayed-type hypersensitivity reactions to tumor-associated antigens in colon carcinoma patients immunized with an autologous tumor cell/Bacillus Calmette-Guérin vaccine. Cancer Res 1993 Feb 1; 53 (3): 456-9
9. 9. Jones RC, Kelley M, Gupta RK, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996 Sep: 3 (5): 437-45
10. 10. Bystryn J, Oratz R, Roses D, et al. Relationship between immune responses to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992 Mar 1; 69 (5): 1157-64
11. 11. McCune CS, ODonnell RW, Marquis DM, et al. Renal-cell carcinoma treated by vaccines for active specific immunotherapy: a correlation of survival with skin testing by autologous tumor. Cancer Immunol Immunother 1990 Oct; 32 (1): 62-6
12. 12. Galligioni E, Quaia M, Merlo A, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guérin: five-year results of a prospective randomized study. Cancer 1996 Jun 15; 77 (12): 2560-6
13. 13. Berd D, Maguire Jr HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986 May; 46: 2572-7
14. 14. Hom SS, Schwartzentruber DJ, Rosenberg SA, et al. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunother 1993 Jan; 13 (1): 18-30
15. 15. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998 Mar; 4 (3): 321-7
16. 16. Blay JY, Negrier S, Combaret V, et al. Serum levels of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992 Jun 15; 52: 3317-22
17. 17. Maffezzini M, Simonato A, Fortis C. Salvage immunotherapy with subcutaneous recombinant interleukins (rIL-2) and alpha-interferon (IFN-α) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 1996 May; 28 (5): 282-6
18. 18. Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkins lymphoma cells and act as cooperative growth factors. Cancer Res 1996 Dec 1; 56 (23): 5499-505
19. 19. Salvi S, Segalla F, Rao S, et al. Overexpression of the T-cell receptor β-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res 1995 Aug 1; 55 (15): 3374-9
20. 20. Sensi M, Salvi S, Chiara C, et al. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T-lymphocyte (CTL) clones: tumor infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanoma-lineage-specific CTL clone. J Exp Med 1993 Oct 1; 178 (4): 1231-46
21. 21. Weidmann E, Logan TF, Yasumura S, et al. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res 1993 Oct 15; 53 (20): 4745-9
22. 22. Parmiani G, Sensi M, Berd D. Oligoclonal expansion of T cells in vaccinated melanoma patients [abstract]. Cancer vaccines meeting; 1996 Oct 7-9; New York City. New York: Cancer Research Institute, 1996
23. 23. Mohler T, Willhauck M, Scheibenbogen C, et al. Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapy. Melanoma Res 1995 Apr: 5: 129-32
24. 24. Kan-Mitchell J, Huang XQ, Steinman L, et al. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother 1993 Jul; 37 (1): 15-25
25. 25. Nishimura MI, Kawakami Y, Charmley P, et al. T-cell receptor repertoire in tumor-infiltrating lymphocytes: analysis of melanoma-specific long-term lines. J Immunother 1994 Aug; 16 (2): 85-94
26. 26. Coulie PG, Somville M, Lehmann F, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 1992 Jan 21; 50 (2): 289-97
27. 27. Mazzocchi A, Belli F, Mascheroni L, et al. Frequency of cytotoxic Tlymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int J Cancer 1994 Aug 1; 58 (3): 330-9
28. 28. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986 Nov; 83 (22): 8694-8
29. 29. Jones PC, Sze LL, Liu PY, et al. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981 Feb; 66 (2): 249-54
30. 30. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage II melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994 May; 12 (5): 1036-44
31. 31. Miller K, Abeles G, Oratz R, et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent cell vaccine. Cancer 1995 Jan 15; 75 (2): 495-502